Abstract:10650 Background: The combination of carboplatin (C), paclitaxel (P) and trastuzumab (T) is active in HER2+ metastatic breast cancer (MBC) (Robert N et al. Proc ASCO 2003), and safer with weekly administration of all 3 agents (Perez E et al. Proc ASCO 2004). The superiority of nanoparticle paclitaxel (Abraxane, AB) over Cremophor-based paclitaxel (Gradishar W et al. JCO 2005), and the efficacy and safety of weekly AB in MBC (Blum J et al. Proc ASCO 2005) motivated us to conduct this study. Materials/Methods: To date 10 of 50 planned patients (pts) with measurable, HER2+ MBC have entered. After we established the safety of AB at 75 mg/m2 on days 1, 8, and 15 every 28 days (n = 4 pts), all subsequent pts received AB at 100 mg/m2. C was dosed at AUC = 2 on the same schedule, and T was weekly at 2 mg/kg without interruption, after a 4 mg/kg load. Initially, no prophylactic anti-allergy medication was given. Treatment is until disease progression (PD) or prohibitive toxicity. Pts without PD at 6 months may opt to continue T alone. Median age: 42 yrs (29–66), ECOG PS 0/1 (70/30%); 6 pts had prior adjuvant chemotherapy; 1 with anthracycline (A) and 4 with A + taxane (> 1 yr prior). Results: 68 cycles have been delivered to date (median: 8, range 1–9). Dose reductions of AB and C have been necessary in 4 pts (to 80 mg/m2 and AUC of 1.5 weekly), with delays in 4 pts. 3 pts had hypersensitivity reactions (HSR) to C and continued protocol therapy without C (n = 2) or with C and the addition of anti-HSR premeds (n = 1). Grade ¾ toxicities include neutropenia (44/11%) with 1 episode of febrile neutropenia. Grade ¾ anemia or thrombocytopenia has not occurred. Grade ¾ non-hematologic toxicity has been rare: 1 instance of grade 3 neuropathy (2 pts with grade 2). 7 partial responses have been observed in the first 9 evaluable pts (78%, 95% CI 44–93%), in liver, lung, bone and soft tissue sites, including 4 pts with prior adjuvant taxane. The median time to PD is not reached at 9.9+ months (7.3–9.9+). Accrual continues as the trial expands to additional study sites. Conclusions: The weekly administration of AB, C, and T demonstrates promising preliminary efficacy as 1st-line treatment for HER2+ MBC. With the exception of HSRs due to weekly C, a very favorable toxicity profile is observed. [Table: see text]

Phase Ii Study of Pseudomonas Aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2-Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Neoadjuvant Pseudomonas Aeruginosa Mannose-Sensitive Hemagglutinin (PA-MSHA) and Chemotherapy Versus Placebo Plus Chemotherapy in Patients with HER2-negative Breast Cancer: a Randomized, Controlled, Double-Blind Trial

247P KN026 in Combination with Docetaxel As Neoadjuvant Treatment for HER2+ Early or Locally Advanced Breast Cancer (BC): A Single-Arm, Multicenter, Phase II Study

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

A Phase II Trial of Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Patients with Chemotherapy-Pretreated Metastatic Breast Cancer.

Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner.

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

Phase II Study of Mitomycin C and Cisplatin in Heavily Pretreated Advanced Breast Cancer

Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer

Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial.

Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

A Phase Ii Study of Triweekly Paclitaxel and Capecitabine Combination Therapy in Patients with Fluoropyrimidine-Platinum-Resistant Metastatic Gastric Adenocarcinoma

Pseudomonas Aeruginosa Preparation Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Randomized, Multicenter, Double-Blind Phase Iii Study

Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer

A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)